 Magenta Therapeutics Inc NASDAQ: MGTA is cutting 14 of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research. 